Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Press releaseGlobeNewswire· July 20, 2026
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
View original at globenewswire.comTelix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer First patient dosed in Phase 3 LUTEON1 trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC).LUTEON is the first Phase 3 study of a CAIX2-targeted radiopharmaceutical therapy in ccRCC…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Dosing the first patient in LUTEON marks an important milestone; despite advances in care, outcomes remain poor for many ccRCC patients, underscoring the need for innovative therapeutic approaches, and the study will evaluate the safety, tolerability and efficacy of TLX250-Tx.
60% confidenceLUTEON represents the next stage in Telix's global clinical development of TLX250-Tx, which is designed to use the high prevalence of CAIX expression in ccRCC to deliver targeted radiation to tumor sites while limiting exposure to healthy tissue.
60% confidence
Cited in these Via News reports
- AI-Designed Biologics and Personalized mRNA Vaccines: What the Oncology Evidence Supports, and What It Doesn't →
- AstraZeneca Says Its Data Will Train Better Cancer Drugs. Its Pitch Rests on a Source That Failed Our Check. →
- AstraZeneca's AI 'Lab of the Future' Meets a Crowded Oncology Pipeline: What Is Proven, and What Is Still a Promise →
- Oncology's Q4 Catalyst Season Meets Pharma's AI Pitch: What Is Verified, and What Is Still a Claim →
